若生智能
Drug Database
PE

PEG IFN alpha-2a (CAP/CTM HCV 2.0)

✓ Approved

Roche · 辅助诊断 · 辅助诊断

什么是 PEG IFN alpha-2a？

PEG IFN alpha-2a 是一种辅助诊断，由Roche研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名CAP/CTM HCV 2.0
公司Roche
药物类别辅助诊断
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Roche

相关研究文献

PubMedClinical science (London, England : 1979)2026-08-04

Combined administration of fructooligosaccharides and Clostridium butyricum attenuates bowel cleansing-induced dysbiosis and safeguards mucosal defense in a murine model.

Xu Xinyu X, Zhou Mingxia M, Zhang Ruoqi R, Liu Wan W et al.

Bowel preparation with polyethylene glycol electrolyte solution (PEG-ELS) is indispensable for gastrointestinal endoscopy and related procedures. However, it disrupts gut microbial homeostasis and increases host vulnerability to ensuing infection. In a murine model, we optimized a synbiotic intervention consisting of fructooligosaccharides (FOS) and Clostridium butyricum (C. butyricum) to improve post-cleansing microbiome resilience and mucosal defense. We evaluated its efficacy and longitudinally monitored the dynamics of gut microbiota in response to bowel cleaning and concurrent bacterial challenge infection. Our data show that the bowel preparation induced a persistent microbial perturbation, resulting in an incomplete spontaneous recovery 15 days after the procedure. A 12-day symbiotic intervention significantly enriched alpha diversity and restored the dysbiosis induced by the cleaning. The intervention also increased Firmicutes/Bacteroidota ratio and the abundance of several key beneficial bacteria in the genera Lactobacillus, Mucispirillum, and Butyricicoccus. Under infectious stress, bowel cleansing markedly aggravated colitis phenotypes, while the intervention alleviated crypt hyperplasia and attenuated inflammatory injury in mice infected with Citrobacter rodentium, resulting in a significant improvement in several colitis indicators. The synbiotic was accompanied by enhanced IL-12/IFN-γ-related antimicrobial responses, increased expression of Muc2 and sIgA, and reshaped bacterial interaction networks disrupted by challenge infection. Our findings demonstrate that the combined administration of FOS and C. butyricum promotes gut microbial homeostasis and host defense. This approach may provide insights into potential dietary strategies for mitigating bowel cleansing-induced microbial disturbances.

PMID 42550055
阅读全文 →
PubMedJournal of molecular neuroscience : MN2026-08-04

Kaempferol-Conjugated Manganese Oxide Nanocomposites Mitigate Aluminium Chloride-Induced Neurobehavioral Impairments in a Rat Model of Alzheimer's disease.

Yu Heng H, Liu Xiufeng X, Liu Juan J, Tang Dong D

The neurodegenerative illness Alzheimer's disease (AD) causes cognitive decline. The production of oxidative stress in neurons is thought to play a role in the emergence of AD. The antioxidants, including kaempferol, reduce the course of AD; however, their use is limited by poor bioavailability. Kaempferol-conjugated manganese oxide nanocomposites (KMF@PEG-MnO2 NCs) exhibit enhanced protective effects against AD compared to free kaempferol. In this study, the potential of KMF@PEG-MnO2 NCs as an anti-Alzheimer's disease (AD) agent was explored through in silico and experimental approaches. The effective preparation of KMF@PEG-MnO2 NCs was validated by FT-IR, XRD, DLS, and SEM-EDX characterization techniques. The influence of KMF@PEG-MnO2 NCs on antioxidant capacity using the DPPH assay, reactive oxygen species (ROS) quantification with the SH-SY5Y cell line, and determining the amyloid β disaggregation was determined. Additionally, blood-brain barrier permeability was assessed with brain endothelial cells, and an anticholinesterase study was performed to explore its potential for treating Alzheimer's disease. Surface characterization revealed a spherical shape of the nanoparticle. DPPH and FR assay showed a substantial rise in antioxidant defence for KMF@PEG-MnO2 NCs compared to KMF. Anti-aggregation studies demonstrated the nanoparticle's ability to inhibit Aβ fibrils. Additionally, the BBB permeability assay indicated that the nanoparticle can permeate the BBB. Furthermore, in vivo studies demonstrated that KMF@PEG-MnO2 NCs protected against cognitive and synaptic deficits in AlCl3-induced AD rats (AlCl₃-AD). KMF@PEG-MnO2 NCs significantly reduced AChE activity. Furthermore, it markedly reduced the brain's levels of nitric oxide (NO) while increasing the function of superoxide dismutase (SOD) and catalase (CAT) activities. Overall, the findings suggest that KMF@PEG-MnO2 NCs may serve as a promising therapeutic candidate for AD management.

PMID 42550339
阅读全文 →
PubMedHepatology (Baltimore, Md.)2026-08-04

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).

Thursz Mark M, Lemoine Maud M, Brown Ashley A, Carey Ivana I et al.

Finite therapy resulting in sustained hepatitis B surface antigen (HBsAg) loss for patients with chronic HBV infection (CHB) is an important therapeutic goal. In patients with HBeAg-negative infection, nucleos(t)ide analogue (NA) withdrawal may achieve HBsAg loss in 5-20% of patients after 3 years. Pegylated interferon (PEG-IFNa) is a recognised treatment for CHB. NUC-B was a randomised, multi-centre trial in NA-treated non-cirrhotic HBeAg negative patients with CHB. Patients were allocated to either NA withdrawal alone (control) or NA withdrawal followed by a 16 week course of PEG-IFNa 180ug weekly commencing 4 weeks after NA cessation (PEG-IFNa). The primary endpoint was HBsAg loss at 3 years. The target recruitment of 240 patients was not achieved. 156 patients, 82 to control arm , 74 to PEG-IFNa arm , were recruited between 2017 and 2021; median age 45 years, 24% female, HBV Genotypes -A 16%, B 6%, C 4%, D 24%, E 22%, other 1%, unknown 26%. At 3 years 3% of patients in the contol arm and 14% of patients in the PEG-IFNa arm lost HBsAg (odds ratio 5.39; 95% confidence interval, (1.11, 26.19); p=0.037). In the control arm 34.9% of patients returned to NA therapy compared to 28.4% in the PEG_IFNa- arm. Exaggerated flares occurred in 27.9% of patients in the control arm compared with 13.4% in the PEG-IFNa arm. The use of adjuvant PEG-IFNa therapy after withdrawal of NA therapy increases the rate of HBsAg loss whilst simultaneously reducing the number of exaggerated flares.

PMID 42549812
阅读全文 →
PubMednpj metabolic health and disease2026-08-04

Overweight and obesity induce Toll-like receptor 2-induced Type I IFN signaling.

Elkins Megan M, Al-Musa Amer A, Chiñas Marcos M, Woods Brian B et al.

Toll-like receptor 2 (TLR2) is an innate immune receptor linked to obesity primarily via NF-κB activation. Using a mouse model of overnutrition and in vitro TLR2 stimulation of human peripheral blood mononuclear cells, we show that lipids, advanced glycation end products, and low-density lipoproteins extend TLR2 signaling beyond NF-κB to promote Type I IFN production and signaling, establishing the relevance of this pathway to human obesity. This response was abolished by pharmacologic inhibition of the receptor for advanced glycation end products, which recognizes glycated proteins and lipids. In vivo dietary reversal, metformin, and tirzepatide each reduced diet-induced inflammation, but differed in their metabolic effects: dietary reversal reduced weight gain and LDL, tirzepatide reduced weight without lowering LDL, and metformin exerted anti-inflammatory effects independent of weight or LDL. These findings identify TLR2-Type I IFN signaling as a feature of diet-induced inflammation and highlight the diverse immunomodulatory effects of weight-management therapies.

PMID 42547779
阅读全文 →
PubMedPreparative biochemistry & biotechnology2026-08-04

Isolation and optimization of L-Asparaginase production from native halotolerant Bacillus subtilis bacteria isolated from Central Iran.

Hosseini Kamran K, Akbarzadehlaleh Parvin P, Hallaj-Nezhadi Somayeh S, Hassanpour Mohsen M et al.

L-Asparaginase is an important enzyme with therapeutic applications. Current commercial enzymes from E. coli and Erwinia chrysanthemi have limitations, such as high glutaminase activity, creating a need for more stable alternatives. This study aimed to isolate and optimize the production of L-Asparaginase from native, halotolerant Bacillus subtilis strains (DAR and D6A) isolated from central Iran, to find an alternative source for this therapeutically important enzyme. The enzyme was initially isolated using polyethylene glycol (PEG) precipitation. Key factors affecting enzyme production were screened using the Plackett-Burman design and subsequently optimized via the Box-Behnken response surface methodology. PEG precipitation at concentrations of 15-20% for PEG 4000/6000 and 10-15% for PEG 8000/10000 was most effective for initial enzyme separation, yielding specific activities of 4.8 U/mg and 5.2 U/mg for strains DAR and D6A, respectively. Optimization revealed that the most influential factors for maximum L-Asparaginase production were 17.6 g/L NaCl, 4.99 g/L KH2PO4, and 10 g/L asparagine for strain DAR, and 1.49 g/L glucose, 10 g/L NaCl, and 9.98 g/L asparagine for strain D6A. The isolated halotolerant B. subtilis strains are capable of producing L-Asparaginase. PEG precipitation is a suitable method for initial purification, and statistical optimization successfully identified the critical culture conditions to enhance enzyme yield significantly. These strains represent promising sources for the production of this clinically valuable enzyme.

PMID 42547854
阅读全文 →
PubMedJCEM case reports2026-08-04

Cutaneous lichen amyloidosis in multiple endocrine neoplasia type 2A.

Mir Uzair Ul Haq UUH, Bhat Mohammad Hayat MH, Mir Shahnaz A SA

PMID 42548782
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PEG IFN alpha-2a